1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
MedRx Co., Ltd

MedRx Co., Ltd

4586.T
MedRx Co., LtdJP flagTokyo Stock Exchange
55.00
JPY
-1.00
- -
3.27BMarket Cap
MedRx Co., Ltd
4586.T
(Tokyo Stock Exchange)

Recent

price

55.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
258.94
30.16
12.51
3.93
5.62
2.76
23.12
0.84
14.12
7.08
0.39
2.35
0.85
5.93
- -
6.6
Revenue per Share
-151.27
-196.25
-113.48
-151.96
-131.21
-155.48
-103.15
-126.77
-134.32
-68.61
-49.62
-43.81
-26.82
-18.56
- -
-13.31
Basic EPS, GAAP
-115.12
-184.73
-124.73
-156.1
-123.65
-150.89
-105.54
-130.33
-149.55
-63.08
-43.37
-42.39
-26.3
-18.49
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-298.57
-489.87
68.84
-95.55
-218.51
-276.08
-340.89
-349.1
-365.7
-298.13
-256.39
-75.83
-1.96
-4.74
- -
8.72
Book Value per Share
295.64
94.55
821.25
524.88
413.83
309.36
237.18
213.05
159.63
132.19
91.56
47.81
55.34
49.92
- -
64.66
Tangible Book Value per Share
3
3
5
7
7
8
9
10
12
16
21
25
35
43
- -
38
Basic Weighted Avg Shares
741
88
69
26
38
22
198
8
170
115
8
59
30
258
128
254
Sales/Revenue/Turnover
-58.66
-646.27
-882.06
-3,816.64
-2,658.65
-6,010.42
-496.14
-15,164.59
-958.42
-982.19
-12,709.29
-1,847.32
-3,160.99
-307.48
-735.45
-232.46
Operating Margin (%)
39
27
28
52
76
58
59
40
40
56
60
46
46
38
14
- -
Depreciation Expense
-433
-571
-622
-1,017
-878
-1,259
-884
-1,268
-1,616
-1,115
-1,060
-1,111
-933
-807
-937
-512
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-58.42
-650.68
-907.03
-3,867.4
-2,335.33
-5,635.74
-446.18
-15,096.89
-951.56
-968.48
-12,692.61
-1,868.04
-3,158.72
-312.8
-731.84
-201.52
Profit Margin (%)
570
57
3,850
2,775
2,094
2,633
1,748
1,768
1,385
1,764
1,629
929
1,685
1,967
1,748
2,186
Working Capital
6
- -
- -
- -
- -
395
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
847
275
4,503
3,514
2,772
2,507
2,034
2,131
1,921
2,147
1,955
1,213
1,925
2,170
2,049
2,487
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-274.22
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
39
44
Market Capitalization
4,566
5,270
6,925

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,785
1,666
2,228
Cash, Cash Equivalents & STI
1,721
1,623
2,166
Accounts Receivable, Net
- -
- -
2
Inventories
10
10
12
Total Current Liabilities
100
38
42
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.28%
3.79%
-5.58%
Free Cash Flow
6.09%
0.04%
20.8%
Net Income, GAAP
3.99%
-2.69%
16.19%
Sales/Revenue/Turnover
373.37%
238.44%
-50.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
231
- -
- -
258
2025
- -
- -
- -
- -
128
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.33
- -
- -
- -
-18.56
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Argent BioPharma Limited (RGT.L)
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)
Alembic Pharmaceuticals Limited (APLLTD.BO)
Dr. Reddy's Laboratories Limited (RDY)
Rekah Pharmaceutical Industry Ltd. (REKA.TA)
PuraPharm Corporation Limited (1498.HK)
Business
MedRx Co., Ltd. MedRx Co., Ltd engages primarily in the research, development, and formulation of pharmaceutical products utilizing advanced transdermal absorption technologies in Japan. The company develops innovative medicines based on its proprietary Ionic Liquid Transdermal System (ILTS) and Nano-sized Colloid Transdermal System (NCTS), which enhance drug solubility, absorbability, and efficacy while minimizing side effects and enabling administration for patients unable to take oral medications; its product pipeline includes MRX-4TZT in phase I clinical trials for spastic paralysis, MRX-9FLT in phase I for chronic, cancer, and severe pain, MRX-7MLL and MRX-6LDT in preclinical stages for Alzheimer’s disease and chronic pain, and MRX-5LBT that has completed clinical trials for postherpetic neuralgia, alongside efforts in painless transdermal delivery for vaccines, nucleic acid medicines, protein medicines, and microneedle array patch vaccines. MedRx Co., Ltd. also explores oral formulations using ionic liquid systems to improve absorbability of challenging active pharmaceutical ingredients (APIs) and seeks partnering opportunities for novel therapies. Founded in 2002 and headquartered in Higashikagawa, Japan, the company operates mainly in the pharmaceuticals sector with a focus on specialty transdermal and advanced drug delivery systems targeting nervous system disorders, pain management, and other unmet medical needs. Recent developments include a 2017 worldwide licensing agreement (excluding East Asia) with Cipla USA Inc. for MRX-4TZT, providing up to USD 30 million in milestone payments and tiered royalties, and a March 2025 private placement of 118,700 units of its 32nd Series Stock Acquisition Rights to raise funds for ongoing operations and development.